 SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today announced that Nancy Thornberry has joined the Board of Directors, effective January 8, 2021. Ms. Thornberrys extensive biotech leadership and pharmaceutical experience includes more than 30 years of development and discovery work in multiple disease areas, including diabetes and endocrinology. 